Navigation Links
Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
Date:4/27/2009

rimental malaria vaccines, most in early pre-clinical testing, to move into a Phase III clinical trial. The trial, which is expected to take three years, is to begin within the next few days among 14,000 infants in Burkina Faso, Ghana, Gabon, Tanzania, Kenya, Malawi and Mozambique. Ballou will discuss the prospects for a malaria vaccine at the NFID meeting at 12:45 p.m. on Wednesday.

"Preliminary studies indicate that it's no longer a question of whether but when we will have a malaria vaccine," said Susan J. Rehm, MD, medical director of NFID and co-chair of the conference. "This is very exciting. Just as encouraging is the progress we are making against such fatal and debilitating diseases as Group A meningitis in Africa. These advances are possible because of important partnerships between academia, private industry, governments, public health officials and philanthropic organizations."

In a keynote address at 8:30 a.m. on Monday, David Salisbury, MBBS, Director of Immunisation for the UK Department of Health in London, discussed accelerated efforts to deliver these and other vaccines to the world's poorest people. Under a three-year-old program initiated by the World Health Organization (WHO) and UNICEF, public-health officials are now targeting individuals of all ages, not just children, for immunization and trying to integrate vaccines with other critical health needs.

Merieux Award to Dr. Paul A. Offit

The conference will honor Paul A. Offit, MD, chief of the division of infectious disease at Children's Hospital of Philadelphia, as this year's recipient of the Charles Merieux Award. Dr. Offit, who is also a professor of pediatrics at the University of Pennsylvania Medical School, co-developed the rotavirus vaccine manufactured by Merck & Co., Inc. He has also been a strong defender of vaccines.

Dr. Offit, who will receive the award at an 1
'/>"/>

SOURCE National Foundation for Infectious Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
6. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
7. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
8. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
11. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... statement by Michael J. Sullivan, Pharmaceutical Industry Labor-Management Association Chair: ... to advance a national  innovation agenda, one that stands to ... part: what can the administration and  Members of Congress specifically ... quality of life for working Americans? The President did a ...
... -- American Oriental Bioengineering, Inc. (NYSE: ... company dedicated to improving healthcare through the development, ... prescription and over-the-counter ("OTC") products, today announced that ... Liu and Chief Financial Officer, Ms. Lily Li ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... the open access journal BMC Medicine has found that the ... in India are flawed and the actual number of cases ... are from the Administrative Staff College of India, conducted the ... Medical Sciences in Hyderabad. ,According to the ...
... of his family served in the Indian Army and battled the ... Sena Medal winner// and with ‘Showrya’ meaning ‘brave’ for a name, ... family path. ,But a fall from the first floor ... the one-and-a-half-year-old Showrya Malik, who was pronounced ‘brain dead’ the next ...
... Pradesh government is considering setting up a medical and health ... Health Minister Ajay Vishnoi said Tuesday. ,"The government ... Medical Council of India for opening the university," Vishnoi told ... workshop on Indian medical systems. ,"The need ...
... are not protected from attacks or stroke by taking a ... ,Folic acid or folate is one of the B Vitamins ... medical practitioners prescribe it to prevent cardiac problems. ... Health and Tropical Medicine, New Orleans led a research on ...
... damaging to health, but obesity has higher damaging properties, ... cancers reducing a person’s life span by seven years ... ,Ken Snider, advisor at NICE i.e. National Institute for ... not only to do with weight loss but also ...
Cached Medicine News:Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:A ‘Brave’ Toddler-The Youngest Organ Don 2Health News:Ways to Fight Childhood Obesity 2
... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
Medicine Products: